CEO
Michael Castagna, Pharm.D., became CEO of MannKind Corporation and joined the company’s board of directors in 2017, bringing more than 25 years’ experience in healthcare, pharmaceuticals and biotechnology to the company’s product and medical device development strategy. Under Michael’s guidance, MannKind is successfully establishing solid partnerships and growing its pipeline, capitalizing on Michael’s extensive knowledge of the commercial pharmaceutical industry. Michael’s deep understanding of the biopharmaceutical industry and dedication to helping people live their lives without limits is grounded by his extensive pharmacy background. Previously, Michael served as a vice president at Amgen, guiding both the Lifecycle Management and Global Commercial Biosimilar business areas of the company. Before Amgen, he spent a combined 10 years at Bristol Myers Squibb, focusing on medical, marketing and sales from 1997 to 2005, returning to the company in 2010 to direct the Immunoscience division from 2010 to 2012. Other industry experience includes serving as a vice president at Sandoz and as a director at Merck, Serono and Pharmasset.